FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200105582> ?p ?o ?g. }

• W4200105582 endingPage "95" @default.
• W4200105582 startingPage "86" @default.
• W4200105582 abstract "Single-dose tafenoquine 300 mg is approved for Plasmodium vivax malaria relapse prevention in patients at least 16 years old. We aimed to determine appropriate oral tafenoquine paediatric dosing regimens, including a dispersible formulation, and evaluated tafenoquine efficacy and safety in children infected with P vivax.This open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 study enrolled children (2-15 years) who weighed 5 kg or more, with glucose-6-phosphate dehydrogenase activity more than 70% of the local population median, and P vivax malaria infection, from three community health centres in Vietnam and one in Colombia. Patients received 3-day chloroquine plus oral single-dose tafenoquine as dispersible tablets (50 mg) or film-coated tablets (150 mg). Dosing groups were assigned by body weight, predicted to achieve similar median exposures as the approved 300 mg dose for adults: patients who weighed 5 kg or more to 10 kg received 50 mg, those who weighed more than 10 to 20 kg received 100 or 150 mg, those who weighed more than 20 to 35 kg received 200 mg, and patients who weighed more than 35 kg received 300 mg. Population pharmacokinetic analysis was done to develop a paediatric population pharmacokinetic model. The primary outcome was the tafenoquine area under the concentration-time curve extrapolated to infinity (AUC[0-∞]) by patient body weight in the pharmacokinetic population (all patients who received tafenoquine with at least one valid pharmacokinetic sample) estimated from a paediatric population pharmacokinetic model. A key prespecified secondary outcome was 4-month recurrence-free efficacy. This trial is registered with ClinicalTrials.gov, NCT02563496.Between Feb 6, 2017, and Feb 17, 2020, 60 patients were enrolled into the study: 14 (23%) received tafenoquine 100 mg, five (8%) 150 mg, 22 (36%) 200 mg, and 19 (32%) 300 mg. The paediatric population pharmacokinetic model predicted adequate tafenoquine exposure at all doses. The predicted median AUC(0-∞) was 73·8 (90% prediction interval [PI] 46·9-117·0) μg × h/mL with the 50 mg dose for patients who weighed 5 kg or more to 10 kg, 87·5 (55·4-139·0) μg × h/mL with the 100 mg dose for body weight more than 10 to 20 kg, 110·7 (70·9-174·0) μg × h/mL with the 200 mg dose for body weight more than 20 to 35 kg, and 85·7 (50·6-151·0) μg × h/mL with the 300 mg dose for body weight more than 35 kg. 4-month recurrence-free efficacy was 94·7% (95% CI 84·6-98·3). Adverse events were consistent with previous studies, except for the seven (12%) of 60 patients who had post-dose vomiting or spitting with the 50 mg dispersed tablet. Following mitigation strategies, there were no additional occurrences of this adverse event. There were no deaths during the study.For the prevention of P vivax relapse in children, single-dose tafenoquine, including a dispersible formulation, had exposure, safety, and efficacy consistent with observations in adolescents and adults, notwithstanding post-dose vomiting.GlaxoSmithKline and Medicines for Malaria Venture.For the Vietnamese and Spanish translations of the abstract see Supplementary Materials section." @default.
• W4200105582 created "2021-12-31" @default.
• W4200105582 creator A5000963667 @default.
• W4200105582 creator A5011659813 @default.
• W4200105582 creator A5012065499 @default.
• W4200105582 creator A5012196488 @default.
• W4200105582 creator A5012532861 @default.
• W4200105582 creator A5018898285 @default.
• W4200105582 creator A5029471638 @default.
• W4200105582 creator A5029531416 @default.
• W4200105582 creator A5036755269 @default.
• W4200105582 creator A5039773092 @default.
• W4200105582 creator A5042780289 @default.
• W4200105582 creator A5046443494 @default.
• W4200105582 creator A5055912135 @default.
• W4200105582 creator A5056799272 @default.
• W4200105582 creator A5068237755 @default.
• W4200105582 creator A5076181892 @default.
• W4200105582 creator A5076846074 @default.
• W4200105582 date "2022-02-01" @default.
• W4200105582 modified "2023-10-16" @default.
• W4200105582 title "Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial" @default.
• W4200105582 cites W1519586906 @default.
• W4200105582 cites W1892471648 @default.
• W4200105582 cites W1969443191 @default.
• W4200105582 cites W2117767554 @default.
• W4200105582 cites W2120416054 @default.
• W4200105582 cites W2162203634 @default.
• W4200105582 cites W2278941756 @default.
• W4200105582 cites W2328008522 @default.
• W4200105582 cites W2462041221 @default.
• W4200105582 cites W2559872714 @default.
• W4200105582 cites W2891817575 @default.
• W4200105582 cites W2891945121 @default.
• W4200105582 cites W2896820459 @default.
• W4200105582 cites W2910452042 @default.
• W4200105582 cites W2910820964 @default.
• W4200105582 cites W2912077025 @default.
• W4200105582 cites W2947406061 @default.
• W4200105582 cites W2966250344 @default.
• W4200105582 cites W2973370959 @default.
• W4200105582 cites W3018160686 @default.
• W4200105582 cites W4211136995 @default.
• W4200105582 doi "https://doi.org/10.1016/s2352-4642(21)00328-x" @default.
• W4200105582 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34871570" @default.
• W4200105582 hasPublicationYear "2022" @default.
• W4200105582 type Work @default.
• W4200105582 citedByCount "7" @default.
• W4200105582 countsByYear W42001055822022 @default.
• W4200105582 countsByYear W42001055822023 @default.
• W4200105582 crossrefType "journal-article" @default.
• W4200105582 hasAuthorship W4200105582A5000963667 @default.
• W4200105582 hasAuthorship W4200105582A5011659813 @default.
• W4200105582 hasAuthorship W4200105582A5012065499 @default.
• W4200105582 hasAuthorship W4200105582A5012196488 @default.
• W4200105582 hasAuthorship W4200105582A5012532861 @default.
• W4200105582 hasAuthorship W4200105582A5018898285 @default.
• W4200105582 hasAuthorship W4200105582A5029471638 @default.
• W4200105582 hasAuthorship W4200105582A5029531416 @default.
• W4200105582 hasAuthorship W4200105582A5036755269 @default.
• W4200105582 hasAuthorship W4200105582A5039773092 @default.
• W4200105582 hasAuthorship W4200105582A5042780289 @default.
• W4200105582 hasAuthorship W4200105582A5046443494 @default.
• W4200105582 hasAuthorship W4200105582A5055912135 @default.
• W4200105582 hasAuthorship W4200105582A5056799272 @default.
• W4200105582 hasAuthorship W4200105582A5068237755 @default.
• W4200105582 hasAuthorship W4200105582A5076181892 @default.
• W4200105582 hasAuthorship W4200105582A5076846074 @default.
• W4200105582 hasBestOaLocation W42001055821 @default.
• W4200105582 hasConcept C112705442 @default.
• W4200105582 hasConcept C126322002 @default.
• W4200105582 hasConcept C203014093 @default.
• W4200105582 hasConcept C2776793103 @default.
• W4200105582 hasConcept C2777288759 @default.
• W4200105582 hasConcept C2777425658 @default.
• W4200105582 hasConcept C2778048844 @default.
• W4200105582 hasConcept C2778371730 @default.
• W4200105582 hasConcept C2779997623 @default.
• W4200105582 hasConcept C2908647359 @default.
• W4200105582 hasConcept C71924100 @default.
• W4200105582 hasConcept C98274493 @default.
• W4200105582 hasConcept C99454951 @default.
• W4200105582 hasConceptScore W4200105582C112705442 @default.
• W4200105582 hasConceptScore W4200105582C126322002 @default.
• W4200105582 hasConceptScore W4200105582C203014093 @default.
• W4200105582 hasConceptScore W4200105582C2776793103 @default.
• W4200105582 hasConceptScore W4200105582C2777288759 @default.
• W4200105582 hasConceptScore W4200105582C2777425658 @default.
• W4200105582 hasConceptScore W4200105582C2778048844 @default.
• W4200105582 hasConceptScore W4200105582C2778371730 @default.
• W4200105582 hasConceptScore W4200105582C2779997623 @default.
• W4200105582 hasConceptScore W4200105582C2908647359 @default.
• W4200105582 hasConceptScore W4200105582C71924100 @default.
• W4200105582 hasConceptScore W4200105582C98274493 @default.
• W4200105582 hasConceptScore W4200105582C99454951 @default.
• W4200105582 hasFunder F4320306882 @default.
• W4200105582 hasFunder F4320307773 @default.
• W4200105582 hasFunder F4320322413 @default.

• next